ACRV net incomeQ2 2026-$17.96M
ACRV net income was -$17.96M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$21.01M a year earlier. For the full fiscal 2025 it was -$77.91M, compared with -$80.56M in fiscal 2024.
Acrivon Therapeutics Inc. (ACRV) financials
For the twelve months ended Jun 30, 2026, Acrivon Therapeutics Inc. reported -$74.22M of net income.
- Net income, TTM
- -$74.22M
- Free cash flow, TTM
- -$64.14M
- EPS, diluted, TTM
- -$1.88
- Cash
- $41.42M
- Market cap
- $67.7M
FY2021FY2025
FY2021FY2025
ACRV revenue and earnings growth
ACRV EPSQ2 2026-$0.43
ACRV diluted EPS was -$0.43 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.55 a year earlier. For the full fiscal 2025 it was -$2.02, compared with -$2.38 in fiscal 2024.
ACRV free cash flowQ2 2026-$14.95M
ACRV free cash flow was -$14.95M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$17.10M a year earlier. For the full fiscal 2025 it was -$65.33M, compared with -$68.44M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Research and development | $59.99M | $63.99M | $46.02M | $23.95M | - |
| Selling, general and admin | $24.12M | $25.21M | $21.08M | $8.71M | - |
| Operating income | -$84.11M | -$89.20M | -$67.10M | -$32.66M | -$16.18M |
| Pre-tax income | -$77.83M | -$80.44M | - | - | - |
| Income tax | $0 | - | - | - | - |
| Net income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | -$16.24M |
| EPS, basic | -$2.02 | -$2.38 | -$2.74 | -$7.56 | -$9.32 |
| EPS, diluted | -$2.02 | -$2.38 | -$2.74 | -$7.56 | -$9.32 |
| Diluted shares | 38.5M | 33.8M | 22.1M | 4.1M | 1.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $41.50M | $39.82M | $36.02M | $29.52M | $99.60M |
| Short-term investments | $77.08M | $139.66M | $91.44M | $98.23M | - |
| Current assets | $120.44M | $181.63M | $129.69M | $132.09M | $100.41M |
| Total assets | $129.72M | $196.59M | $138.26M | $181.23M | $106.59M |
| Current liabilities | $15.66M | $17.21M | $13.30M | $6.52M | $2.91M |
| Total liabilities | $17.20M | $19.80M | $17.07M | $10.75M | $7.88M |
| Shareholders' equity | $112.52M | $176.79M | $121.19M | $170.47M | -$23.81M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$63.66M | -$65.67M | -$42.64M | -$30.12M | -$13.98M |
| Capital expenditures | $1.67M | $2.77M | $1.29M | $2.17M | $238.0K |
| Free cash flow | -$65.33M | -$68.44M | -$43.93M | -$32.28M | -$14.22M |
| Investing cash flow | $66.10M | -$51.77M | $50.72M | -$141.68M | -$238.0K |
| Financing cash flow | -$749.0K | $121.03M | -$1.55M | $101.71M | $112.22M |
| Stock-based compensation | $14.72M | $14.29M | $11.62M | $2.19M | $497.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $13.84M | $15.17M | $14.75M | $13.65M | $16.18M | $15.41M | $18.63M | $18.86M | $15.03M | $11.47M | $15.48M | $10.27M |
| Selling, general and admin | $4.82M | $4.74M | $5.37M | $6.04M | $6.47M | $6.25M | $6.32M | $6.28M | $6.41M | $6.20M | $5.58M | $5.87M |
| Operating income | -$18.67M | -$19.90M | -$20.12M | -$19.69M | -$22.65M | -$21.66M | -$24.95M | -$25.14M | -$21.44M | -$17.67M | -$21.05M | -$16.14M |
| Net income | -$17.96M | -$19.04M | -$18.98M | -$18.23M | -$21.01M | -$19.68M | -$22.83M | -$22.44M | -$18.80M | -$16.49M | -$19.25M | -$14.47M |
| EPS, basic | -$0.43 | -$0.49 | -$0.49 | -$0.47 | -$0.55 | -$0.51 | - | -$0.59 | -$0.52 | -$0.73 | -$0.87 | -$0.66 |
| EPS, diluted | -$0.43 | -$0.49 | -$0.49 | -$0.47 | -$0.55 | -$0.51 | - | -$0.59 | -$0.52 | -$0.73 | -$0.87 | -$0.66 |
| Diluted shares | 41.8M | 38.7M | - | 38.6M | 38.5M | 38.4M | - | 38.1M | 36.1M | 22.6M | - | 22.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $41.42M | $34.06M | $41.50M | $35.41M | $41.90M | $39.15M | $39.82M | $43.41M | $46.01M | $24.61M | $36.02M | $29.86M |
| Short-term investments | $48.54M | $63.67M | $77.08M | $93.85M | $95.53M | $110.48M | $139.66M | $144.04M | $134.53M | $85.37M | $91.44M | $112.23M |
| Current assets | $91.49M | $99.22M | $120.44M | $130.36M | $138.41M | $151.33M | $181.63M | $188.98M | $182.36M | $112.14M | $129.69M | $144.49M |
| Total assets | $99.09M | $107.83M | $129.72M | $145.30M | $158.58M | $176.35M | $196.59M | $214.68M | $230.59M | $120.52M | $138.26M | $151.09M |
| Current liabilities | $11.45M | $11.05M | $15.66M | $14.89M | $13.43M | $13.55M | $17.21M | $14.82M | $11.28M | $9.04M | $13.30M | $9.30M |
| Total liabilities | $12.43M | $12.32M | $17.20M | $16.70M | $15.55M | $15.96M | $19.80M | $17.79M | $14.53M | $12.54M | $17.07M | $12.94M |
| Shareholders' equity | $86.67M | $95.52M | $112.52M | $128.60M | $143.04M | $160.39M | $176.79M | $196.89M | $216.06M | $107.98M | $121.19M | $138.15M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.86M | -$20.54M | -$15.24M | -$12.28M | -$16.61M | -$19.54M | -$17.36M | -$17.32M | -$13.90M | -$17.08M | -$12.37M | -$9.81M |
| Capital expenditures | $87.0K | $14.0K | $219.0K | $899.0K | $493.0K | $58.0K | $827.0K | $989.0K | $137.0K | $815.0K | $1.15M | $0 |
| Free cash flow | -$14.95M | -$20.55M | -$15.46M | -$13.18M | -$17.10M | -$19.59M | -$18.19M | -$18.31M | -$14.04M | -$17.90M | -$13.52M | -$9.81M |
| Investing cash flow | $14.95M | $13.13M | $21.52M | $5.91M | $19.45M | $19.21M | $14.41M | $16.01M | -$88.04M | $5.85M | $20.54M | $1.52M |
| Financing cash flow | $7.27M | -$33.0K | -$192.0K | -$117.0K | -$97.0K | -$343.0K | -$647.0K | -$1.50M | $123.35M | -$172.0K | -$2.01M | $78.0K |
| Stock-based compensation | $2.21M | $2.18M | $3.09M | $3.91M | $3.93M | $3.79M | $3.71M | $3.67M | $3.57M | $3.34M | $3.06M | $3.23M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.99 | 8.98 | 7.69 | 8.75 | 10.31 | 11.17 | 10.55 | 12.75 | 16.16 | 12.40 | 9.75 | 15.54 |
Source: XBRL data Acrivon Therapeutics Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ACRV peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ACRV | - | - | -$74.22M | - | $67.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
ACRV FAQ
6 questionsIs ACRV profitable?
No. Acrivon Therapeutics Inc. reported a net loss of $74.22M for the twelve months ended Jun 30, 2026.How much cash and debt does ACRV have?
Acrivon Therapeutics Inc. reported $41.42M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ACRV free cash flow?
Acrivon Therapeutics Inc. generated -$64.14M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$62.92M less capital expenditures.What is ACRV earnings per share?
Diluted earnings per share were -$1.88 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ACRV last report financial results?
The latest statements here come from Acrivon Therapeutics Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this ACRV financial data come from?
Quantisnow builds these statements from the structured XBRL data Acrivon Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.